Methylation of DNA repair genes during tumour development might lead to drug sensitivity, as disseminated single ovarian cancer tumor cells with functional BRCA1 have a higher chemoresistance and might be selected for during therapy. This evidence concerns the gene BRCA1 and ovarian carcinoma.